Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

149.94 +2.42 (+1.64%)
Streaming Delayed Price Updated: 2:16 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nasdaq Biotechnology Ishares ETF

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
3 Biotech ETFs Overdue for a Bounce
The biotech ETFs have been under serious pressure in recent years. Newfound momentum and looming lower rates could spark a comeback. 
Via InvestorPlace
Topics ETFs
Millionaire Makers: 3 Sectors Poised for 20X Gains
Dive into three explosive sectors that could yield 20X returns for the bold investor. Uncover these potential millionaire makers. 
Via InvestorPlace
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
Lottery Preference And Biotech Stocks: Trust The Financials, Not The Science
Making a bet on biotech/pharma firms that have not yet achieved significant revenue is the equivalent of buying a lottery ticket—with the same poor risk/return relationship. 
Via Talk Markets
Healthcare Stocks Are Looking Better But What About Biotech?
Large cap biopharmacuiticals remain a core holding for growth and value despite political cross-currents on drug pricing. 
Via Talk Markets
Has The Solar ETF TAN Bottomed?
The last swing high before the huge parabolic move in TAN in 2020 was exactly where the current price was. 
Via Talk Markets
Topics ETFs
The Transportation Sector Has A Story To Tell
With the market experiencing a dose of reality on interest rates, we still believe that current rates are not the worst news for the market, depending on where you look. 
Via Talk Markets
Healthcare And Life Science Funds And ETFs Performance 2023-2024
Healthcare stocks usually provide a defensive posture to a stock portfolio. 
Via Talk Markets
Topics ETFs
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top Thematic ETF Ideas For 2024
With AI adoption and spending expected to expand this year, new avenues for business growth will open up for tech companies beyond the Magnificent Seven. 
Via Talk Markets
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Bullish Continuation In '24? 3 Market Areas To Watch
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
Markets: Week 1 Week 2 - What's Next Week 3?
The growth space is getting crowded again, while the 
Via Talk Markets
A Rough Start To 2024 What Might Be In Store For The Rest Of 2024?
The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year. 
Via Talk Markets
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
US Stocks Eye 3-Day Slump; Tech, Crypto Sell-Off Deepens, Oil, Dollar Rebound: What's Driving Markets Wednesday?
The early 2024 sell-off is intensifying on Wall Street, with all major stock averages in the red on the second trading day of 2024. 
Via Benzinga
Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
Wall Street kicked off 2024 on a weaker note, with the S&P 500 dipping by 0.5%, and the Nasdaq 100 experiencing a 1.4% decline in midday trading in New York. 
Via Benzinga
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
Wall Street Sees Post-Holiday Gains, Oil Rallies, Intel Leads: What's Driving Markets Tuesday?
The U.S. stock market saw modest gains in a session characterized by low trading volumes following the Christmas holiday. The S&P 500 Index gained 0.3% during midday trading in New York, eyeing its... 
Via Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
US Stocks Bounce; Chipmakers, Cruise Lines Lead, Dollar Falls: What's Driving Markets Thursday?
On Thursday, Wall Street rebounded into positive territory, following a brief dip experienced on Wednesday. At midday trading New York time, all major stock indices were trading in the green as traders... 
Via Benzinga
Wall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?
Stocks inched higher during midday trading in New York on Wednesday, with the momentum carrying over from the previous day when the tech-heavy Nasdaq 100 achieved fresh record highs. 
Via Benzinga
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
MarketBeat Week in Review – 12/4 - 12/8
Stocks finished in the green to close the week; investors believe the jobs report will allow the Fed to leave interest rates unchanged when they meet next week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Biotech reversal confirmed: what's ahead for the IBB?
The recent reversal and reclaim of the significant $124 support level in the IBB holds importance, indicating a potential shift in momentum. 
Via MarketBeat
Topics ETFs
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
You Don't Have to Pick a Winner in Biotech. Here's Why.
If you invest over the long term, you'll increase your chances of victory. 
Via The Motley Fool
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.